Panacea Biotec · NSE: PANACEABIO · BSE: 531349
Q3 FY23 results · Oct–Dec 2022
Panacea Biotec reported revenue from operations of ₹115.20 crore (down 26.1% from Q3 FY22) and net profit of ₹19.37 crore for Q3 FY23 (Oct–Dec 2022), on a consolidated basis.
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 115.20 | 155.88 | −26.1% | 105.12 | +9.6% |
| Other income | 13.94 | 1.66 | +739.8% | 10.45 | +33.4% |
| Total income | 129.14 | 157.54 | −18.0% | 115.57 | +11.7% |
| Profit before tax | 22.44 | (49.16) | Turned profit | 23.31 | −3.7% |
| Net profit for the period | 19.37 | (49.20) | Turned profit | 15.70 | +23.4% |
| EPS, basic (₹) | 3.16 | (8.03) | Turned profit | 2.56 | +23.4% |
| Net margin (%) | 16.8 | -31.6 | 14.9 |
| Item | Q3 FY23 | Q3 FY22 | YoY | Q2 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 71.97 | 38.48 | +87.0% | 48.74 | +47.7% |
| Other income | 9.71 | 2.38 | +308.0% | 7.92 | +22.6% |
| Total income | 81.68 | 40.86 | +99.9% | 56.66 | +44.2% |
| Profit before tax | 13.24 | (22.43) | Turned profit | (6.85) | Turned profit |
| Net profit for the period | 13.24 | (22.43) | Turned profit | (6.85) | Turned profit |
| EPS, basic (₹) | 2.16 | (3.66) | Turned profit | (1.12) | Turned profit |
| Net margin (%) | 18.4 | -58.3 | -14.1 |
Consolidated
- Filed with BSE
- 17 Feb 2023, 12:30 IST
- Board meeting
- 14 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 Feb 2023, 12:30 IST
- Board meeting
- 14 Feb 2023
- Period
- 01 Oct 2022 to 31 Dec 2022
- Review status
- Unaudited
- Source
- XBRL filing on BSE